Patient Guide
Clinical Trials and Research Participation
Phases, informed consent, your rights, and relation to standard care
Clinical trials systematically test new drugs, combinations, devices, or approaches. Participation is voluntary; declining should not block standard care. Ethics review and informed consent are mandatory.
“Last resort” is not always the right frame — some trials exist in earlier settings. Clarify the standard alternative, arms, extra visits, and toxicity monitoring in writing.
Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Figure summary
- Stage and prior therapies
- Biomarker / molecular fit
- Organ function and performance status
- Travel / visit burden
When are trials discussed?
When standard options are limited, a biologic subtype is targetable, or new combinations are being studied, your team may screen for suitable trials. Not every patient fits every study — inclusion and exclusion criteria are strict.
- Stage and prior therapies
- Biomarker / molecular fit
- Organ function and performance status
- Travel / visit burden
Phases in brief
Phase I focuses on safety and dose; Phase II on efficacy signals; Phase III on comparison with standard care. Earlier phases carry more unknowns. Phase number alone is not a quality guarantee — read the protocol summary.
Your rights
Read consent forms without rush; ask about anything unclear. You may withdraw anytime without needing to justify. Withdrawal should not close standard-care access. Data handling follows protocol and privacy rules.
- Voluntary participation
- Withdrawal anytime
- Standard care access should remain
- Write your questions down
Questions to ask
What is the standard alternative? Is there a placebo or blinding? How often are extra scans / blood tests? Who monitors toxicity around the clock? Is travel support available? How will results be shared with you?
Realistic expectations
A trial is not a promise of miracle cure. Some arms may match or beat standard care; some may not. Benefit–risk is discussed against the protocol, your stage, and your values.
Common questions
Are trials only a last resort?
Sometimes, but appropriate trials also exist in earlier settings. The label does not fit every protocol.
If I decline, will care worsen?
No. Declining should not affect access to standard treatment.
If there is a placebo arm, will I get no drug?
Oncology designs vary; many add to standard care or use active comparators. Clarify in the consent form.
Who pays?
Research-related extras are often covered by the sponsor / site; routine care items may differ — ask in writing.
Evidence
Scientific sources
Show sources · 1Ethics and patient-rights framing for clinical trial participation and informed consent.
Evidence
Scientific sources
- 1. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEuropean Society for Medical Oncology (ESMO) · 2023 · DOI: 10.1016/j.annonc.2022.10.003Open source →
Last reviewed: 22 October 2026. Links go to publisher pages.
This guide is for education only and is not medical advice, diagnosis, or treatment. Written instructions specific to your surgery take priority. Seek urgent care without delay for emergency symptoms.